Cargando…
SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects
BACKGROUND: The detoxification of very long-chain and branched-chain fatty acids and the metabolism of cholesterol to form bile acids occur largely through a process called peroxisomal β-oxidation. Mutations in several peroxisomal proteins involved in β-oxidation have been reported, resulting in dis...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396802/ https://www.ncbi.nlm.nih.gov/pubmed/35996156 http://dx.doi.org/10.1186/s40246-022-00408-w |
_version_ | 1784772000770686976 |
---|---|
author | Galano, Melanie Ezzat, Shereen Papadopoulos, Vassilios |
author_facet | Galano, Melanie Ezzat, Shereen Papadopoulos, Vassilios |
author_sort | Galano, Melanie |
collection | PubMed |
description | BACKGROUND: The detoxification of very long-chain and branched-chain fatty acids and the metabolism of cholesterol to form bile acids occur largely through a process called peroxisomal β-oxidation. Mutations in several peroxisomal proteins involved in β-oxidation have been reported, resulting in diseases characterized by neurological defects. The final step of the peroxisomal β-oxidation pathway is catalyzed by sterol carrier protein-x (SCPx), which is encoded by the SCP2 gene. Previously, there have been two reports of SCPx deficiency, which resulted from a homozygous or compound heterozygous SCP2 mutation. We report herein the first patient with a heterozygous SCP2 mutation leading to SCPx deficiency. RESULTS: Clinical presentations of the patient included progressive brainstem neurodegeneration, cardiac dysrhythmia, muscle wasting, and azoospermia. Plasma fatty acid analysis revealed abnormal values of medium-, long-, and very long-chain fatty acids. Protein expression of SCPx and other enzymes involved in β-oxidation were altered between patient and normal fibroblasts. RNA sequencing and lipidomic analyses identified metabolic pathways that were altered between patient and normal fibroblasts including PPAR signaling, serotonergic signaling, steroid biosynthesis, and fatty acid degradation. Treatment with fenofibrate or 4-hydroxytamoxifen increased SCPx levels, and certain fatty acid levels in patient fibroblasts. CONCLUSIONS: These findings suggest that the patient’s SCP2 mutation resulted in decreased protein levels of SCPx, which may be associated with many metabolic pathways. Increasing SCPx levels through pharmacological interventions may reverse some effects of SCPx deficiency. Collectively, this work provides insight into many of the clinical consequences of SCPx deficiency and provides evidence for potential treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40246-022-00408-w. |
format | Online Article Text |
id | pubmed-9396802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93968022022-08-24 SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects Galano, Melanie Ezzat, Shereen Papadopoulos, Vassilios Hum Genomics Research BACKGROUND: The detoxification of very long-chain and branched-chain fatty acids and the metabolism of cholesterol to form bile acids occur largely through a process called peroxisomal β-oxidation. Mutations in several peroxisomal proteins involved in β-oxidation have been reported, resulting in diseases characterized by neurological defects. The final step of the peroxisomal β-oxidation pathway is catalyzed by sterol carrier protein-x (SCPx), which is encoded by the SCP2 gene. Previously, there have been two reports of SCPx deficiency, which resulted from a homozygous or compound heterozygous SCP2 mutation. We report herein the first patient with a heterozygous SCP2 mutation leading to SCPx deficiency. RESULTS: Clinical presentations of the patient included progressive brainstem neurodegeneration, cardiac dysrhythmia, muscle wasting, and azoospermia. Plasma fatty acid analysis revealed abnormal values of medium-, long-, and very long-chain fatty acids. Protein expression of SCPx and other enzymes involved in β-oxidation were altered between patient and normal fibroblasts. RNA sequencing and lipidomic analyses identified metabolic pathways that were altered between patient and normal fibroblasts including PPAR signaling, serotonergic signaling, steroid biosynthesis, and fatty acid degradation. Treatment with fenofibrate or 4-hydroxytamoxifen increased SCPx levels, and certain fatty acid levels in patient fibroblasts. CONCLUSIONS: These findings suggest that the patient’s SCP2 mutation resulted in decreased protein levels of SCPx, which may be associated with many metabolic pathways. Increasing SCPx levels through pharmacological interventions may reverse some effects of SCPx deficiency. Collectively, this work provides insight into many of the clinical consequences of SCPx deficiency and provides evidence for potential treatment strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40246-022-00408-w. BioMed Central 2022-08-22 /pmc/articles/PMC9396802/ /pubmed/35996156 http://dx.doi.org/10.1186/s40246-022-00408-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Galano, Melanie Ezzat, Shereen Papadopoulos, Vassilios SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects |
title | SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects |
title_full | SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects |
title_fullStr | SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects |
title_full_unstemmed | SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects |
title_short | SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects |
title_sort | scp2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396802/ https://www.ncbi.nlm.nih.gov/pubmed/35996156 http://dx.doi.org/10.1186/s40246-022-00408-w |
work_keys_str_mv | AT galanomelanie scp2variantisassociatedwithalterationsinlipidmetabolismbrainstemneurodegenerationandtesticulardefects AT ezzatshereen scp2variantisassociatedwithalterationsinlipidmetabolismbrainstemneurodegenerationandtesticulardefects AT papadopoulosvassilios scp2variantisassociatedwithalterationsinlipidmetabolismbrainstemneurodegenerationandtesticulardefects |